A randomized, double-blind, placebo-controlled, mechanistic trial on the safety, tolerability and pharmacodynamics of ninerafaxstat in patients with angina and chronic coronary syndrome

Back

ESC Premium Access

A randomized, double-blind, placebo-controlled, mechanistic trial on the safety, tolerability and pharmacodynamics of ninerafaxstat in patients with angina and chronic coronary syndrome

Session: Pharmacotherapy in coronary artery disease: from bench to bedside (1)

Topic: Pharmacotherapy

Speaker: Professor A. Saraste (Turku, FI)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Professor Antti Saraste

Turku University Hospital, Turku (Finland)

14 presentations

0 follower

8 more presentations in this session

Platelet membrane coated r-SAK to improve thrombolytic efficacy by targeting thrombus

Speaker: Miss R. Hua (Nanjing, CN)

AtheroVax: a peptide vaccine with a therapeutic effect in animal model of chronic inflammation

Speaker: Professor E. Ramacciotti (Santo Andre, BR)

Sodium-glucose cotransporter 2 inhibitor attenuates left ventricular dysfunction in post-myocardial infarction in rats via reducing cardiac mitochondrial impairment

Speaker: Doctor C. Maneechote (Chiang Mai, TH)

A new free radical scavenger, resorcimoline, prevents ischaemia/reperfusion injury in the heart

Speaker: Doctor K. Ueno (Oita, JP)

Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy

Speaker: Professor R. Storey (Sheffield, GB)

Access the full session

Pharmacotherapy in coronary artery disease: from bench to bedside (1)

Speakers: Professor A. Saraste, Miss R. Hua, Professor E. Ramacciotti, Doctor C. Maneechote, Doctor K. Ueno...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources